|4.01|| +0.01 / +0.25%|
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of actual pain. Its lead product candidate includes ZalvisoTM intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system. It is designed to address the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA. AcelRx Pharmaceuticals was founded by Thomas A. Schreck and Pamela P. Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
|Howard B. Rosen||Chief Executive Officer & Director|
|Timothy E. Morris||CFO & Head-Business Development|
|Pamela Pierce Palmer||Director & Chief Medical Officer|
|Mark A. Evashenk||Vice President-Clinical Operations|
|Carter J. King||Vice President-Corporate Development|